AtriCure
1D
1W
1M
3M
YTD
1Y
5Y
ALL
Why Robinhood?
Robinhood gives you the tools you need to put your money in motion. You can buy or sell AtriCure and other ETFs, options, and stocks.About ATRC
AtriCure, Inc. engages in the development, manufacture, and sale of surgical ablation of cardiac tissue, and systems for the exclusion of the left atrial appendage. Its products include radio frequency (RF) ablation pacing and sensing, cryo, left atrial appendage management, soft tissue dissection, estech surgical instrumentation, and cart configuration.
CEOMichael H. Carrel
CEOMichael H. Carrel
Employees1,300
Employees1,300
HeadquartersMason, Ohio
HeadquartersMason, Ohio
Founded1994
Founded1994
Employees1,300
Employees1,300
ATRC Key Statistics
Market cap1.63B
Market cap1.63B
Price-Earnings ratio-54.05
Price-Earnings ratio-54.05
Dividend yield—
Dividend yield—
Average volume815.90K
Average volume815.90K
High today—
High today—
Low today—
Low today—
Open price$32.16
Open price$32.16
Volume0.00
Volume0.00
52 Week high$43.11
52 Week high$43.11
52 Week low$28.29
52 Week low$28.29
Stock Snapshot
The current AtriCure(ATRC) stock price is $32.86, with a market capitalization of 1.63B. The stock trades at a price-to-earnings (P/E) ratio of -54.05.
On 2025-11-12, AtriCure(ATRC) shares started trading at $32.16, with intraday highs of — and lows of —.
Trading activity shows a volume of 0, compared to an average daily volume of 815.9K.
The stock's 52-week range extends from a low of $28.29 to a high of $43.11.
The stock's 52-week range extends from a low of $28.29 to a high of $43.11.
ATRC News
Simply Wall St 2d
AtriCure Is Down 5.8% After Raising Revenue Guidance and Narrowing Net Loss – Has The Bull Case Changed?AtriCure, Inc. recently reported third quarter 2025 results with sales rising to US$134.27 million and a significant reduction in net loss compared to the same...
Analyst ratings
100%
of 9 ratingsBuy
100%
Hold
0%
Sell
0%
People also own
Based on the portfolios of people who own ATRC. This list is generated using Robinhood data, and it’s not a recommendation.